In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type.
Where this comes from
- Record sourced from PubMed, PMID 38560913.
- Also identified by DOI 10.7326/J24-0020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
EMPA-KIDNEY Collaborative Group. <b>Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.</b> Lancet Diabetes Endocrinol. 2024;12:51-60. 38061372.
Medical subject headings
- Diabetes Mellitus, Type 2
- Cardiovascular Diseases
- Renal Insufficiency, Chronic
- Benzhydryl Compounds
- Glucosides